Hk Inno-N

Hk Inno-N company information, Employees & Contact Information

Explore related pages

Related company profiles:

Since its establishment in 1984, HK inno.N Corp. has tapped into the belief that its business was also helping chart the nation’s future. This belief has served and continues to serve the company well, as it has grown into one of the leading pharmaceutical firms in the nation. Since its establishment in 1984, HK inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products. Drawing on the company’s experience and knowhow in developing novel drugs, HK inno.N succeeded in launching ‘K-CAB’, the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, HK inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.

Company Details

Employees
198
Founded
-
Address
중구 을지로 100, 서울,04551,korea, Republic Of
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
서울
Looking for a particular Hk Inno-N employee's phone or email?

Hk Inno-N Questions

News

HK inno.N expands GLP-1 drug to diabetes; Q2 profit drops on beverage recall - koreabiomed.com

HK inno.N expands GLP-1 drug to diabetes; Q2 profit drops on beverage recall koreabiomed.com

HK inno.N Expands Latin American Launch of GERD Drug K-CAB - NAVLIN DAILY

HK inno.N Expands Latin American Launch of GERD Drug K-CAB NAVLIN DAILY

HK inno.N, Pfizer Korea sign co-promotion deal for updated Covid-19 vaccine - koreabiomed.com

HK inno.N, Pfizer Korea sign co-promotion deal for updated Covid-19 vaccine koreabiomed.com

Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India - The Hindu

Dr. Reddy’s introduces Korean firm HK inno.N’s APD drug Tegoprazan in India The Hindu

HK inno.N's K-CAB completes successful Phase 3 trials, FDA application imminent - CHOSUNBIZ - Chosun Biz

HK inno.N's K-CAB completes successful Phase 3 trials, FDA application imminent - CHOSUNBIZ Chosun Biz

HK inno.N's K-CAB to get insurance benefits in China - The Korea Economic Daily Global Edition

HK inno.N's K-CAB to get insurance benefits in China The Korea Economic Daily Global Edition

HK inno.N’s K-CAB debuts in India with Dr. Reddy’s - koreabiomed.com

HK inno.N’s K-CAB debuts in India with Dr. Reddy’s koreabiomed.com

HK inno.N to begin phase 3 trial of obesity drug in 300 patients in Korea - koreabiomed.com

HK inno.N to begin phase 3 trial of obesity drug in 300 patients in Korea koreabiomed.com

HK inno.N’s K-CAB tops standard acid treatment in US reflux trials, FDA filing next - koreabiomed.com

HK inno.N’s K-CAB tops standard acid treatment in US reflux trials, FDA filing next koreabiomed.com

HK inno.N’s K-CAB clears US trial hurdle, eyeing FDA filing this year - koreabiomed.com

HK inno.N’s K-CAB clears US trial hurdle, eyeing FDA filing this year koreabiomed.com

HK inno.N moves topical JAK inhibitor into phase 2 for atopic dermatitis - koreabiomed.com

HK inno.N moves topical JAK inhibitor into phase 2 for atopic dermatitis koreabiomed.com

Phathom blocks generics with FDA win, paving way for HK inno.N’s rival acid reflux launch in US - koreabiomed.com

Phathom blocks generics with FDA win, paving way for HK inno.N’s rival acid reflux launch in US koreabiomed.com

HK inno.N becomes largest shareholder of Japan’s RaQualia to boost R&D, K-CAB expansion - koreabiomed.com

HK inno.N becomes largest shareholder of Japan’s RaQualia to boost R&D, K-CAB expansion koreabiomed.com

HK inno.N fends off generics in K-CAB patent clash, securing 2nd win in court - koreabiomed.com

HK inno.N fends off generics in K-CAB patent clash, securing 2nd win in court koreabiomed.com

Roche Korea and HK inno.N form partnership for Avastin promotion - koreabiomed.com

Roche Korea and HK inno.N form partnership for Avastin promotion koreabiomed.com

HK inno.N's GERD drug enters Australian and New Zealand markets - koreabiomed.com

HK inno.N's GERD drug enters Australian and New Zealand markets koreabiomed.com

HK inno.N’s GERD drug K-CAB recommended for approval in India - koreabiomed.com

HK inno.N’s GERD drug K-CAB recommended for approval in India koreabiomed.com

HK inno.N acquires Novacell Technology’s immunotherapy candidate - koreabiomed.com

HK inno.N acquires Novacell Technology’s immunotherapy candidate koreabiomed.com

HK inno.N signs new Covid-19 vaccine supply agreement with Pfizer - koreabiomed.com

HK inno.N signs new Covid-19 vaccine supply agreement with Pfizer koreabiomed.com

HK inno.N speeds up developing homegrown obesity drug - koreabiomed.com

HK inno.N speeds up developing homegrown obesity drug koreabiomed.com

HK inno.N’s CAR-T cell therapy chosen as state-subsidized new drug project - koreabiomed.com

HK inno.N’s CAR-T cell therapy chosen as state-subsidized new drug project koreabiomed.com

HK inno.N addresses growth concerns following patent suit setback - koreabiomed.com

HK inno.N addresses growth concerns following patent suit setback koreabiomed.com

HK inno.N completes P3 trial for new indication of GERD drug K-CAB - koreabiomed.com

HK inno.N completes P3 trial for new indication of GERD drug K-CAB koreabiomed.com

HK inno.N launches GERD drug K-CAB in 6 more Latin American countries - koreabiomed.com

HK inno.N launches GERD drug K-CAB in 6 more Latin American countries koreabiomed.com

HK inno.N reveals differentiated clinical results for K-CAB - The Korea Economic Daily Global Edition

HK inno.N reveals differentiated clinical results for K-CAB The Korea Economic Daily Global Edition

Y-Biologics, HK inno.N, and IMBiologics finalize $315.5M technology transfer for autoimmune disease drug with Chinese drugmaker - koreabiomed.com

Y-Biologics, HK inno.N, and IMBiologics finalize $315.5M technology transfer for autoimmune disease drug with Chinese drugmaker koreabiomed.com

HK inno.N’s reflux therapy hits Indian market - The Korea Herald

HK inno.N’s reflux therapy hits Indian market The Korea Herald

HK inno.N to exclusively market Roche's flu treatment in Korea - koreabiomed.com

HK inno.N to exclusively market Roche's flu treatment in Korea koreabiomed.com

HK inno.N to release K-CAB in MENA market - The Korea Economic Daily Global Edition

HK inno.N to release K-CAB in MENA market The Korea Economic Daily Global Edition

HK inno.N’s K-CAB a blockbuster drug with $843 million exports - The Korea Economic Daily Global Edition

HK inno.N’s K-CAB a blockbuster drug with $843 million exports The Korea Economic Daily Global Edition

HK inno.N to introduce biosimilars for bone disease treatment from Spain - The Korea Economic Daily Global Edition

HK inno.N to introduce biosimilars for bone disease treatment from Spain The Korea Economic Daily Global Edition

HK inno.N’s GERD drug K-CAB gets sales nod in Chile - koreabiomed.com

HK inno.N’s GERD drug K-CAB gets sales nod in Chile koreabiomed.com

Boryung, HK inno.N to co-market their flagship hypertension and GERD drugs - koreabiomed.com

Boryung, HK inno.N to co-market their flagship hypertension and GERD drugs koreabiomed.com

Sciwind Biosciences & HK inno.N ink $56 M deal to treat metabolic diseases in Korea - BioSpectrum Asia

Sciwind Biosciences & HK inno.N ink $56 M deal to treat metabolic diseases in Korea BioSpectrum Asia

HK inno.N wins phase 3 nod for eczema drug in dogs to take on Zoetis' Apoquel - koreabiomed.com

HK inno.N wins phase 3 nod for eczema drug in dogs to take on Zoetis' Apoquel koreabiomed.com

HK inno.N Acquires Major Stake in RaQualia, cementing Ties for GERD Treatment Development - Businesskorea

HK inno.N Acquires Major Stake in RaQualia, cementing Ties for GERD Treatment Development Businesskorea

HK inno.N’s K-CAB chosen as outstanding technology leading Korean industry - koreabiomed.com

HK inno.N’s K-CAB chosen as outstanding technology leading Korean industry koreabiomed.com

[Best Brand] HK inno.N’s anti-aging products make overseas foray - The Korea Herald

[Best Brand] HK inno.N’s anti-aging products make overseas foray The Korea Herald

HK inno.N's K-CAB tablets win sale approval in Mexico - Korea JoongAng Daily

HK inno.N's K-CAB tablets win sale approval in Mexico Korea JoongAng Daily

HK inno.N says it confirmed K-Cab’s safety in US trial - koreabiomed.com

HK inno.N says it confirmed K-Cab’s safety in US trial koreabiomed.com

HK inno.N’s GERD treatment K-CAB approved in Malaysia - koreabiomed.com

HK inno.N’s GERD treatment K-CAB approved in Malaysia koreabiomed.com

HK inno.N licenses in GLP-1 analog from Chinese biotech - koreabiomed.com

HK inno.N licenses in GLP-1 analog from Chinese biotech koreabiomed.com

inno.N to co-develop ‘global’ anticancer therapy with Voronoi - koreabiomed.com

inno.N to co-develop ‘global’ anticancer therapy with Voronoi koreabiomed.com

HK inno.N’s ‘K-CAB’ Officially Launched in India - Businesskorea

HK inno.N’s ‘K-CAB’ Officially Launched in India Businesskorea

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada - PR Newswire

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada PR Newswire

HK inno.N partners with Roche Korea to distribute Tamiflu - koreabiomed.com

HK inno.N partners with Roche Korea to distribute Tamiflu koreabiomed.com

HK inno.N to export K-CAB to India and six other markets - koreabiomed.com

HK inno.N to export K-CAB to India and six other markets koreabiomed.com

HK inno.N signs deal to produce Brexogen's exosome therapy - koreabiomed.com

HK inno.N signs deal to produce Brexogen's exosome therapy koreabiomed.com

HK inno.N’s K-CAB Succeeds in U.S. Phase 3 Trial - Businesskorea

HK inno.N’s K-CAB Succeeds in U.S. Phase 3 Trial Businesskorea

HK inno.N’s IPO price set at top end with record demand for Kosdaq listing - The Korea Economic Daily Global Edition

HK inno.N’s IPO price set at top end with record demand for Kosdaq listing The Korea Economic Daily Global Edition

HK inno.N poised to bolster S.Korea's IPO lineup in H2 - The Korea Economic Daily Global Edition

HK inno.N poised to bolster S.Korea's IPO lineup in H2 The Korea Economic Daily Global Edition

HK inno.N Q3 Earnings to Shine on ‘K-CAB Effect’ - 코메디닷컴

HK inno.N Q3 Earnings to Shine on ‘K-CAB Effect’ 코메디닷컴

HK inno.N publishes P3 trial results of drug on gastric ulcers - koreabiomed.com

HK inno.N publishes P3 trial results of drug on gastric ulcers koreabiomed.com

HK inno.N plans 2021 IPO with $1.8 bn valuation - The Korea Economic Daily Global Edition

HK inno.N plans 2021 IPO with $1.8 bn valuation The Korea Economic Daily Global Edition

inno.N, JW Life Science vye for No. 1 title in IV fluid output - koreabiomed.com

inno.N, JW Life Science vye for No. 1 title in IV fluid output koreabiomed.com

HK inno.N, Y Biologics "tie up" to find next-generation immune-cancer antibodies - koreabiomed.com

HK inno.N, Y Biologics "tie up" to find next-generation immune-cancer antibodies koreabiomed.com

K-CAB Surge and Vaccine Distribution Put HK inno.N on the Verge of ₩1 Trillion in Annual Sales - 코메디닷컴

K-CAB Surge and Vaccine Distribution Put HK inno.N on the Verge of ₩1 Trillion in Annual Sales 코메디닷컴

HK inno.N releases K-Cab in Singapore - The Korea Economic Daily Global Edition

HK inno.N releases K-Cab in Singapore The Korea Economic Daily Global Edition

HK inno.N gets approval to sell K-CAB in Singapore - The Korea Economic Daily Global Edition

HK inno.N gets approval to sell K-CAB in Singapore The Korea Economic Daily Global Edition

CJ Healthcare changes name to HK inno.N - koreabiomed.com

CJ Healthcare changes name to HK inno.N koreabiomed.com

HK inno.N aiming to monopolize GERD market launches K-CAB in Indonesia - koreabiomed.com

HK inno.N aiming to monopolize GERD market launches K-CAB in Indonesia koreabiomed.com

HK inno.N's GERD drug K-CAB gets approval in Mexico - The Korea Economic Daily Global Edition

HK inno.N's GERD drug K-CAB gets approval in Mexico The Korea Economic Daily Global Edition

Dr Reddys Labs, HK inno.N Corporation ink pact to commercialize Tegoprazan in India, 6 key emerging... - Medical Dialogues

Dr Reddys Labs, HK inno.N Corporation ink pact to commercialize Tegoprazan in India, 6 key emerging... Medical Dialogues

Top Hk Inno-N Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant